1. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID‐19 convalescent plasma clinical trial
- Author
-
Nai-Ying Zheng, Jeffrey B. Matthews, John C. Alverdy, Amy Durkin-Celauro, Geoffrey D. Wool, Mari Cobb, Henry A. Utset, David O. Meltzer, Won Hee Oh, Jessica S. Donington, Mark K. Ferguson, Patrick C. Wilson, Kumaran Shanmugarajah, Scott Matushek, Maud O. Jansen, Haley L. Dugan, John P. Kress, Micah T. Prochaska, Cindy Bethel, Kathleen G. Beavis, John F. Fung, Diego di Sabato, Janani Vigneswaran, Maria Lucia Madariaga, Dustin G. Shaw, Madan Kumar, Jenna J. Guthmiller, Laura Trockman, Jiaolong Wang, Stephen Schrantz, Chancey Christensen, Mihai Giurcanu, Olivia Stovicek, and Robert Keskey
- Subjects
0301 basic medicine ,myalgia ,Adult ,Male ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,antibody titre ,Antibodies, Viral ,Gastroenterology ,Serology ,COVID-19 Serological Testing ,03 medical and health sciences ,0302 clinical medicine ,COVID‐19 ,Internal medicine ,ABO blood group system ,medicine ,Internal Medicine ,Humans ,COVID-19 Serotherapy ,Aged ,Blood type ,biology ,business.industry ,SARS-CoV-2 ,Immunization, Passive ,COVID-19 ,Original Articles ,Middle Aged ,Antibodies, Neutralizing ,United States ,Clinical trial ,Titer ,030104 developmental biology ,Treatment Outcome ,Immunoglobulin G ,Toxicity ,convalescent plasma ,Antibody Formation ,biology.protein ,Original Article ,Female ,Antibody ,medicine.symptom ,Symptom Assessment ,business - Abstract
Background Convalescent plasma therapy for COVID‐19 relies on transfer of anti‐viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID‐19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial. Methods Multivariable analysis of clinical and serological parameters in 103 confirmed COVID‐19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed‐effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID‐19. Results Donor antibody titres ranged from 0 to 1 : 3892 (anti‐receptor binding domain (RBD)) and 0 to 1 : 3289 (anti‐spike). Higher anti‐RBD and anti‐spike titres were associated with increased age, hospitalization for COVID‐19, fever and absence of myalgia (all P
- Published
- 2020